Alan Ezekowitz, M.D., Ph.D., is currently a venture partner at Third Rock Ventures, LLC, a healthcare venture firm, an Entrepreneur in Residence at Cardinal Partners, a venture capital firm, an adviser to Fidelity’s Select Biotechnology Portfolio, and as a consultant to H. Lundbeck A/S. From 2011 to 2019, Dr. Ezekowitz was Co-Founder and CEO of Abide Therapeutics, Inc., a biopharmaceutical company acquired by Lundbeck LLC in 2019. Prior to co-founding Abide, he was a Senior Vice President at Merck Research Laboratories responsible for the Bone, Respiratory, Immunology, Inflammation, Endocrine and Dermatology franchises. Prior to his time at Merck, Dr. Ezekowitz was the Chief of Pediatric Services at Partner Healthcare System, Inc. (1999 to 2006) and at the Massachusetts General Hospital (1995-2006). From 2000 to 2006, Dr. Ezekowitz served on the board of directors of Partners Healthcare System, Inc, and from 1995 to 2006, he was the Charles Wilder Professor of Pediatrics at Harvard Medical School and Head of the Laboratory of Developmental Immunology, with over 150 publications in the field of innate immunity. He currently serves on the board of directors of Fulcrum Therapeutics, Inc. (since 2016). Dr. Ezekowitz was born in South Africa, educated at the University of Cape Town in South Africa, and earned his Doctor of Philosophy at the University of Oxford in the United Kingdom.